Other Events ·
Citius Oncology reports sustained quality of life improvements for LYMPHIR in CTCL patients
CTXRCitius Pharmaceuticals, Inc.
Citius Pharmaceuticals' majority-owned subsidiary, Citius Oncology, announced health-related quality of life results from pivotal Study 302 of LYMPHIR (denileukin diftitox-cxdl) in adults with relapsed or refractory cutaneous T-cell lymphoma. Presented at the EORTC-CLTG 2026 Annual Meeting, data showed that among responders, patients reported sustained improvements in skin-related and overall quality of life measures compared to non-responders. Additionally, nearly a third (32%) of heavily pretreated patients with significant itch noted a clinically meaningful decrease in pruritus. Citius Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products.